ACTIV-6: COVID-19 Study of Repurposed Medications

Trial ID or NCT#

NCT04885530

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID. Pro00107921_A - Arm D (Ivermectin 400) - NCT05736861; Pro00107921_B - Arm B (Fluvoxamine) - NCT05890586; Pro00107921_C - Arm C (Fluticasone) - NCT05736874; Pro00107921_D - Arm D (Ivermectin 600) - NCT05894538; Pro00107921_E - Arm E (Fluvoxamine 100) - NCT05894564; Pro00107921_F - Arm F (Montelukast) - NCT05894577; Pro00107921_G - Arm G (Metformin) - NCT06042855.

Official Title

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Eligibility Criteria

Ages Eligible for Study: Older than 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Completed Informed Consent - Age ≥ 30 years old - Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening - Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell
Exclusion Criteria:
  1. - Current or recent (within 10 days of screening) hospitalization for COVID-19 infection - Current or planned participation in another interventional trial to treat COVID-19, at the discretion of the study principal investigator (PI) - Current or recent use (within the last 14 days) of study drug or study drug/device combination - Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo - Known contraindication(s) to study drug including prohibited concomitant medications - Previous or current enrollment in the ACTIV-6 trial
View All Criteria
Show Less

Investigator(s)

Upinder Singh
Upinder Singh
Infectious disease doctor
Stanford Medicine Professor of Infectious Disease and Professor of Medicine (Infectious Diseases & Geographic Medicine) and of Microbiology and Immunology

View on ClinicalTrials.gov